Cargando…

Cost Effectiveness of Tofacitinib for the Treatment of Moderate to Severe Active Ulcerative Colitis in Colombia

OBJECTIVE: The aim of this study was to evaluate the cost effectiveness of tofacitinib versus other treatment options currently available in Colombia in naïve to biologics (first-line) and exposed to biologics (second-line) patients with moderate to severe active ulcerative colitis (UC). METHODS: A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gil, Fabio, Juliao-Baños, Fabian, Amador, Luisa, Castano, Natalia, Reyes, Juan Manuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596638/ https://www.ncbi.nlm.nih.gov/pubmed/35943702 http://dx.doi.org/10.1007/s41669-022-00360-4

Ejemplares similares

Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis
por: Vong, Camille, et al.
Publicado: (2021)

Initial experience of tofacitinib for treating refractory moderate-to-severe ulcerative colitis
por: Nakamura, Masanao, et al.
Publicado: (2022)

Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis
por: Rubin, David T., et al.
Publicado: (2021)

Infliximab, adalimumab, golimumab, vedolizumab and tofacitinib in moderate to severe ulcerative colitis: comparative cost-effectiveness study in Poland
por: Petryszyn, Pawel, et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan
por: Kobayashi, Taku, et al.
Publicado: (2023)

Evaluating tofacitinib citrate in the treatment of moderate-to-severe active ulcerative colitis: design, development and positioning of therapy
por: Tran, Vivy, et al.
Publicado: (2019)

Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis
por: Chiorean, Michael V., et al.
Publicado: (2022)

The role and prospect of tofacitinib in patients with ulcerative colitis
por: Lee, Jun
Publicado: (2023)

Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib
por: Winthrop, Kevin L, et al.
Publicado: (2018)

Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation
por: Lohan, Christoph, et al.
Publicado: (2019)

Correction to: Real-world characteristics, treatment experiences and corticosteroid utilisation of patients treated with tofacitinib for moderate to severe ulcerative colitis
por: Chiorean, Michael V., et al.
Publicado: (2022)

Clostridium difficile Infection in Patients with Ulcerative Colitis Treated with Tofacitinib in the Ulcerative Colitis Program
por: Loftus, Edward V, et al.
Publicado: (2022)

Tofacitinib in Steroid-Refractory Acute Severe Ulcerative Colitis: A Retrospective Analysis
por: Malakar, Sayan, et al.
Publicado: (2023)

Use of Tofacitinib for the Treatment of Arthritis Associated With Ulcerative Colitis
por: Wang, Wenfei, et al.
Publicado: (2019)

Clinical Case of Tofacitinib Therapy in Autoimmune Alopecia in Patient with Ulcerative Colitis
por: Bodryagina, Evgenia, et al.
Publicado: (2022)

Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme
por: Winthrop, Kevin L, et al.
Publicado: (2020)

Tofacitinib in Treatment-Refractory Moderate to Severe Ulcerative Colitis: Real-World Experience from a Retrospective Multicenter Observational Study
por: Hoffmann, Peter, et al.
Publicado: (2020)

Correction: Tofacitinib for the treatment of moderately to severely active ulcerative colitis: a systematic review, network meta-analysis and economic evaluation
Publicado: (2020)

Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data
por: Curtis, Jeffrey R, et al.
Publicado: (2020)

Tofacitinib, two-faced Janus in ulcerative colitis and Crohn’s disease?
por: Biemans, Vince BC, et al.
Publicado: (2020)

Review article: guide to tofacitinib dosing in patients with ulcerative colitis
por: Irving, Peter M., et al.
Publicado: (2022)

Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative Colitis
por: Sandborn, William J, et al.
Publicado: (2021)

Exposure–response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose‐ranging phase 2 trial
por: Mukherjee, Arnab, et al.
Publicado: (2018)

Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry
por: Biemans, Vince B. C., et al.
Publicado: (2020)

Effectiveness and Safety of Tofacitinib in the Management of Ulcerative Colitis: A Brazilian Observational Multicentric Study
por: Perin, Ramir Luan, et al.
Publicado: (2022)

Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical Program
por: Sands, Bruce E, et al.
Publicado: (2021)

Impact of biological agents and tofacitinib for moderate-to-severe ulcerative colitis on health-related quality of life: a protocol for a network meta-analysis
por: Ma, Xueni, et al.
Publicado: (2021)

Exposure‐Response Characterization of Tofacitinib Efficacy in Moderate to Severe Ulcerative Colitis: Results From Phase II and Phase III Induction and Maintenance Studies
por: Mukherjee, Arnab, et al.
Publicado: (2022)

Tofacitinib for induction of remission in ulcerative colitis: systematic review and meta-analysis
por: Paschos, Paschalis, et al.
Publicado: (2018)

Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme
por: Sandborn, William J., et al.
Publicado: (2019)

Tofacitinib-Associated Iatrogenic Kaposi Sarcoma in a Patient With Ulcerative Colitis
por: Wetwittayakhlang, Panu, et al.
Publicado: (2021)

Worldwide post‐marketing safety surveillance experience with tofacitinib in ulcerative colitis
por: Rubin, David T., et al.
Publicado: (2021)

Fulminant Demodex folliculitis in a patient with ulcerative colitis treated with tofacitinib
por: Neudorfer, Carolina, et al.
Publicado: (2023)

Long-term Risk of Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib
por: Winthrop, Kevin L, et al.
Publicado: (2022)

Successful initial tofacitinib treatment for acute severe ulcerative colitis with steroid resistance: a case series
por: Komeda, Yoriaki, et al.
Publicado: (2023)

Tofacitinib Response in Ulcerative Colitis (TOUR): Early Response After Initiation of Tofacitinib Therapy in a Real-world Setting
por: Long, Millie D, et al.
Publicado: (2022)

Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis
por: Mahadevan, Uma, et al.
Publicado: (2018)

Profile of Tofacitinib in the Treatment of Ulcerative Colitis: An Evidence-Based Review of Recent Data
por: Varyani, Fumi, et al.
Publicado: (2019)

Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis
por: Shimizu, Hiromichi, et al.
Publicado: (2021)

Effects of Dextran Sulfate Sodium-Induced Ulcerative Colitis on the Disposition of Tofacitinib in Rats
por: Bae, Sung Hun, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_th31mihvrmqbg5a854h56ve9tr